DOCSLIB.ORG

Regulation of Cancer Stemness in Breast Ductal Carcinoma in Situ by Vitamin D Compounds

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Regulation of Cancer Stemness in Breast Ductal Carcinoma in Situ by Vitamin D Compounds Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Analysis of the Transcriptome: Regulation of Cancer Stemness in Breast Ductal Carcinoma In Situ by Vitamin D Compounds Naing Lin Shan1, Audrey Minden1,5, Philip Furmanski1,5, Min Ji Bak1, Li Cai2,5, Roman Wernyj1, Davit Sargsyan3, David Cheng3, Renyi Wu3, Hsiao-Chen D. Kuo3, Shanyi N. Li3, Mingzhu Fang4, Hubert Maehr1, Ah-Ng Kong3,5, Nanjoo Suh1,5 1Department of Chemical Biology, Ernest Mario School of Pharmacy; 2Department of Biomedical Engineering, School of Engineering; 3Department of Pharmaceutics, Ernest Mario School of Pharmacy; 4Environmental and Occupational Health Sciences Institute and School of Public Health, 5Rutgers Cancer Institute of New Jersey, New Brunswick; Rutgers, The State University of New Jersey, NJ, USA Running title: Regulation of cancer stemness by vitamin D compounds Key words: Breast cancer, cancer stemness, gene expression, DCIS, vitamin D compounds Financial Support: This research was supported by the National Institutes of Health grant R01 AT007036, R01 AT009152, ES005022, Charles and Johanna Busch Memorial Fund at Rutgers University and the New Jersey Health Foundation. Corresponding author: Dr. Nanjoo Suh, Department of Chemical Biology, Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, 164 Frelinghuysen Road, Piscataway, New Jersey 08854. Tel: 848-445-8030, Fax: 732-445-0687; e-mail: [email protected] Disclosure of Conflict of Interest: “The authors declare no potential conflicts of interest” 1 Downloaded from cancerpreventionresearch.aacrjournals.org on September 27, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Article Type: Research Article Word count: 5,286 Total number of figures and tables: Figures-4 and Tables-2 2 Downloaded from cancerpreventionresearch.aacrjournals.org on September 27, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. ABSTRACT Ductal carcinoma in situ (DCIS), which accounts for one out of every five new breast cancer diagnoses, will progress to potentially lethal invasive ductal carcinoma (IDC) in about 50% of cases. Vitamin D compounds have been shown to inhibit progression to IDC in the MCF10DCIS model. This inhibition appears to involve a reduction in the cancer stem cell-like population in MCF10DCIS tumors. To identify genes that are involved in the vitamin D effects, a global transcriptomic analysis was undertaken of MCF10DCIS cells grown in mammosphere cultures, in which cancer stem-like cells grow preferentially and produce colonies by self-renewal and maturation, in the presence and absence of 1α25(OH)2D3 and a vitamin D analog, BXL0124. Using next-generation RNA sequencing, we found that vitamin D compounds down-regulated genes involved in maintenance of breast cancer stem-like cells (e.g. GDF15), epithelial-mesenchymal transition, invasion and metastasis (e.g. LCN2, S100A4), chemo- resistance (e.g. NGFR, PPP1R1B, AGR2), while up-regulating genes associated with a basal-like phenotype (e.g. KRT6A, KRT5) and negative regulators of breast tumorigenesis (e.g. EMP1). Gene methylation status was analyzed to determine whether the changes in expression induced by vitamin D compounds occurred via this mechanism. Ingenuity pathway analysis was performed to identify upstream regulators and downstream signaling pathway genes differentially regulated by vitamin D, including TP63 and vitamin D receptor (VDR) mediated canonical pathways in particular. This study provides a global profiling of changes in the gene signature of DCIS regulated by vitamin D compounds and possible targets for chemoprevention of DCIS progression to IDC in patients. 3 Downloaded from cancerpreventionresearch.aacrjournals.org on September 27, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Introduction Breast cancer is the most common cancer and the second leading cause of cancer related deaths in women worldwide [1]. Based on the presence or absence of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor-2 (HER2), breast cancers are divided into subtypes: luminal A (ER+ and/or PR+; HER2–), luminal B (ER+ and/or PR+; HER2+), basal-like (ER–, PR–, and HER2–), and HER2-enriched (ER–, PR–, and HER2+) [2]. Breast cancer development is a multi-step process that involves epigenetic and genetic changes contributing to aberrant cell growth [3]. Histologically, breast cancer can be staged into invasive ductal carcinoma, ductal carcinoma in situ (DCIS) and invasive lobular carcinoma. About 20% of breast cancers newly diagnosed in 2019 among US women will be classified as DCIS, amounting to over 48,000 cases [4]. DCIS is an early stage, non- invasive type characterized by proliferation of malignant epithelial cells in the ducts [5]. It arises from atypical ductal hyperplasia and may progress to invasive ductal carcinoma (IDC) and metastatic cancer [5]. It is predicted that up to 50% of the DCIS cases will progress to IDC within 10 years of initial diagnosis [6]. Gene expression and microRNA analyses have been performed to elucidate the molecular characteristics of DCIS progression to IDC [7, 8]. However, the natural history of progression of DCIS to IDC is yet to be fully determined. Cancer stem cells (CSCs) were first identified in breast cancer using the cell surface markers CD44+/CD24- [9]. This population is characterized by a stem-cell gene expression signatures, drug- resistant phenotype and self-renewal capacity in vitro and in vivo [10]. Human DCIS lesions form spheroids and duct-like structures in ex vivo organoid culture and tumors in immunodeficient mice, suggestive of the presence of CSC-like cells in these early tumors [11]. MCF10DCIS.COM was derived from the non-tumorigenic MCF10A human breast cell line and exhibits basal-like subtype properties [12]. It is similar to human DCIS with bi-potentiality that can give rise to both myoepithelial and luminal cells and spontaneous progression to invasive breast cancer in vivo [13], and it is widely used as a model for IDC development from precursor lesions. MCF10DCIS.COM cultures and tumors contain high ALDH1+ 4 Downloaded from cancerpreventionresearch.aacrjournals.org on September 27, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. and CD44+/CD49f+/CD24− subpopulations with increased self-renewal and tumor development capabilities, similar to CSCs of fully invasive tumors [14]. Vitamin D signaling is known to be a potential target for breast cancer chemoprevention [15]. Our laboratory has shown that vitamin D compounds inhibit triple negative breast cancer tumorigenesis by reducing expression of cancer stem-cell associated genes, including OCT4 and CD44, and by inducing differentiation and up-regulating myoepithelial markers [16]. These compounds reduce in vitro mammosphere formation and in vivo tumorigenesis, although the molecular mechanisms of these effects are not known. BXL0124 is an analog of calcitriol (1α25(OH)2D3) modified with an additional side chain at C21-methyl group, endowing it with more biological activity at lower concentrations without causing hypercalcemia, a limiting side effect of vitamin D [17]. BXL0124 also inhibits MCF10DCIS xenograft tumorigenesis more potently than 1α25(OH)2D3, apparently through the similar mechanism of suppressing cancer stem cells [18]. The present study was undertaken to develop global profiles of changes in gene expression and CpG methylation in MCF10DCIS cells induced by vitamin D compounds, to gain an understanding of the pathways involved in their overall effects and the molecular basis of their activities, and to identify potential targets that could be exploited in the chemoprevention of breast cancer progression from DCIS to IDC. Materials and methods Reagents and cell culture 1α25(OH)2D3 and a Gemini vitamin D analog (BXL0124; 1α,25-dihydroxy-20R-21(3-hydroxy-3- deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-cholecalciferol, >95% purity) were provided by BioXell, Inc. (Nutley, NJ) [17]. Vitamin D compounds were dissolved in DMSO. MCF10DCIS.com human breast cancer cells (MCF10DCIS, RRID: CVCL_5552) were provided by Dr. Fred Miller at the Barbara Ann Karmanos Cancer Institute (Detroit, MI). Cells were maintained in DMEM/F12 medium supplemented with 5% horse serum, 1% penicillin/streptomycin, and 1% HEPES 5 Downloaded from cancerpreventionresearch.aacrjournals.org on September 27, 2021. © 2020 American Association for Cancer Research. Author Manuscript Published OnlineFirst on May 28, 2020; DOI: 10.1158/1940-6207.CAPR-19-0566 Author manuscripts have been peer reviewed and accepted for publication but have not yet been
Load more

Recommended publications
  • Hearing Aging Is 14.1±0.4% GWAS-Heritable
    medRxiv preprint doi: https://doi.org/10.1101/2021.07.05.21260048; this version posted July 7, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC 4.0 International license . Predicting age from hearing test results with machine learning reveals the genetic and environmental factors underlying accelerated auditory aging Alan Le Goallec1,2+, Samuel Diai1+, Théo Vincent1, Chirag J. Patel1* 1Department of Biomedical Informatics, Harvard Medical School, Boston, MA, 02115, USA 2Department of Systems, Synthetic and Quantitative Biology, Harvard University, Cambridge, MA, 02118, USA +Co-first authors *Corresponding author Contact information: Chirag J Patel [email protected] Abstract With the aging of the world population, age-related hearing loss (presbycusis) and other hearing disorders such as tinnitus become more prevalent, leading to reduced quality of life and social isolation. Unveiling the genetic and environmental factors leading to age-related auditory disorders could suggest lifestyle and therapeutic interventions to slow auditory aging. In the following, we built the first machine learning-based hearing age predictor by training models to predict chronological age from hearing test results (root mean squared error=7.10±0.07 years; R-Squared=31.4±0.8%). We defined hearing age as the prediction outputted by the model on unseen samples, and accelerated auditory aging as the difference between a participant’s hearing age and age. We then performed a genome wide association study [GWAS] and found that accelerated hearing aging is 14.1±0.4% GWAS-heritable.
    [Show full text]
  • Nuclear and Mitochondrial Genome Defects in Autisms
    UC Irvine UC Irvine Previously Published Works Title Nuclear and mitochondrial genome defects in autisms. Permalink https://escholarship.org/uc/item/8vq3278q Journal Annals of the New York Academy of Sciences, 1151(1) ISSN 0077-8923 Authors Smith, Moyra Spence, M Anne Flodman, Pamela Publication Date 2009 DOI 10.1111/j.1749-6632.2008.03571.x License https://creativecommons.org/licenses/by/4.0/ 4.0 Peer reviewed eScholarship.org Powered by the California Digital Library University of California THE YEAR IN HUMAN AND MEDICAL GENETICS 2009 Nuclear and Mitochondrial Genome Defects in Autisms Moyra Smith, M. Anne Spence, and Pamela Flodman Department of Pediatrics, University of California, Irvine, California In this review we will evaluate evidence that altered gene dosage and structure im- pacts neurodevelopment and neural connectivity through deleterious effects on synap- tic structure and function, and evidence that the latter are key contributors to the risk for autism. We will review information on alterations of structure of mitochondrial DNA and abnormal mitochondrial function in autism and indications that interactions of the nuclear and mitochondrial genomes may play a role in autism pathogenesis. In a final section we will present data derived using Affymetrixtm SNP 6.0 microar- ray analysis of DNA of a number of subjects and parents recruited to our autism spectrum disorders project. We include data on two sets of monozygotic twins. Col- lectively these data provide additional evidence of nuclear and mitochondrial genome imbalance in autism and evidence of specific candidate genes in autism. We present data on dosage changes in genes that map on the X chromosomes and the Y chro- mosome.
    [Show full text]
  • Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood
    pathogens Article Transcriptomic Profiling of Equine and Viral Genes in Peripheral Blood Mononuclear Cells in Horses during Equine Herpesvirus 1 Infection Lila M. Zarski 1, Patty Sue D. Weber 2, Yao Lee 1 and Gisela Soboll Hussey 1,* 1 Department of Pathobiology and Diagnostic Investigation, Michigan State University, East Lansing, MI 48824, USA; [email protected] (L.M.Z.); [email protected] (Y.L.) 2 Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI 48824, USA; [email protected] * Correspondence: [email protected] Abstract: Equine herpesvirus 1 (EHV-1) affects horses worldwide and causes respiratory dis- ease, abortions, and equine herpesvirus myeloencephalopathy (EHM). Following infection, a cell- associated viremia is established in the peripheral blood mononuclear cells (PBMCs). This viremia is essential for transport of EHV-1 to secondary infection sites where subsequent immunopathol- ogy results in diseases such as abortion or EHM. Because of the central role of PBMCs in EHV-1 pathogenesis, our goal was to establish a gene expression analysis of host and equine herpesvirus genes during EHV-1 viremia using RNA sequencing. When comparing transcriptomes of PBMCs during peak viremia to those prior to EHV-1 infection, we found 51 differentially expressed equine genes (48 upregulated and 3 downregulated). After gene ontology analysis, processes such as the interferon defense response, response to chemokines, the complement protein activation cascade, cell adhesion, and coagulation were overrepresented during viremia. Additionally, transcripts for EHV-1, EHV-2, and EHV-5 were identified in pre- and post-EHV-1-infection samples. Looking at Citation: Zarski, L.M.; Weber, P.S.D.; micro RNAs (miRNAs), 278 known equine miRNAs and 855 potentially novel equine miRNAs were Lee, Y.; Soboll Hussey, G.
    [Show full text]
  • Anti-ARL4A Antibody (ARG41291)
    Product datasheet [email protected] ARG41291 Package: 100 μl anti-ARL4A antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ARL4A Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P Host Rabbit Clonality Polyclonal Isotype IgG Target Name ARL4A Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 121-200 of Human ARL4A (NP_001032241.1). Conjugation Un-conjugated Alternate Names ARL4; ADP-ribosylation factor-like protein 4A Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 23 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol ARL4A Gene Full Name ADP-ribosylation factor-like 4A Background ADP-ribosylation factor-like 4A is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL4A is similar to ARL4C and ARL4D and each has a nuclear localization signal and an unusually high guaninine nucleotide exchange rate.
    [Show full text]
  • Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-Like Mouse Models: Tracking the Role of the Hairless Gene
    University of Tennessee, Knoxville TRACE: Tennessee Research and Creative Exchange Doctoral Dissertations Graduate School 5-2006 Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene Yutao Liu University of Tennessee - Knoxville Follow this and additional works at: https://trace.tennessee.edu/utk_graddiss Part of the Life Sciences Commons Recommended Citation Liu, Yutao, "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino- like Mouse Models: Tracking the Role of the Hairless Gene. " PhD diss., University of Tennessee, 2006. https://trace.tennessee.edu/utk_graddiss/1824 This Dissertation is brought to you for free and open access by the Graduate School at TRACE: Tennessee Research and Creative Exchange. It has been accepted for inclusion in Doctoral Dissertations by an authorized administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact [email protected]. To the Graduate Council: I am submitting herewith a dissertation written by Yutao Liu entitled "Molecular and Physiological Basis for Hair Loss in Near Naked Hairless and Oak Ridge Rhino-like Mouse Models: Tracking the Role of the Hairless Gene." I have examined the final electronic copy of this dissertation for form and content and recommend that it be accepted in partial fulfillment of the requirements for the degree of Doctor of Philosophy, with a major in Life Sciences. Brynn H. Voy, Major Professor We have read this dissertation and recommend its acceptance: Naima Moustaid-Moussa, Yisong Wang, Rogert Hettich Accepted for the Council: Carolyn R.
    [Show full text]
  • PRRT2 Gene and Protein in Human: Characteristics, Evolution and Function Yinchao Li1, Shuda Chen1, Chengzhe Wang1, Peiling Wang1,Xili1 and Liemin Zhou1,2*
    Li et al. Acta Epileptologica (2021) 3:7 https://doi.org/10.1186/s42494-021-00042-4 Acta Epileptologica RESEARCH Open Access PRRT2 gene and protein in human: characteristics, evolution and function Yinchao Li1, Shuda Chen1, Chengzhe Wang1, Peiling Wang1,XiLi1 and Liemin Zhou1,2* Abstract Background: This study was designed to characterize human PRRT2 gene and protein, in order to provide theoretical reference for research on regulation of PRRT2 expression and its involvement in the pathogenesis of paroxysmal kinesigenic dyskinesia and other related diseases. Method: Biological softwares Protparam, Protscale, MHMM, SignalP 5.0, NetPhos 3.1, Swiss-Model, Promoter 2.0, AliBaba2.1 and EMBOSS were used to analyze the sequence characteristics, transcription factors of human PRRT2 and their binding sites in the promoter region of the gene, as well as the physicochemical properties, signal peptides, hydrophobicity property, transmembrane regions, protein structure, interacting proteins and functions of PRRT2 protein. Results: (1) Evolutionary analysis of PRRT2 protein showed that the human PRRT2 had closest genetic distance from Pongo abelii. (2) The human PRRT2 protein was an unstable hydrophilic protein located on the plasma membrane. (3) The forms of random coil (67.65%) and alpha helix (23.24%) constituted the main secondary structure elements of PRRT2 protein. There were also multiple potential phosphorylation sites in the protein. (4) The results of ontology analysis showed that the cellular component of PRRT2 protein was located in the plasma membrane; the molecular function of PRRT2 included syntaxin-1 binding and SH3 domain binding; the PRRT2 protein is involved in biological processes of negative regulation of soluble NSF attachment protein receptor (SNAR E) complex assembly and calcium-dependent activation of synaptic vesicle fusion.
    [Show full text]
  • PRRT2 Gene Proline Rich Transmembrane Protein 2
    PRRT2 gene proline rich transmembrane protein 2 Normal Function The PRRT2 gene provides instructions for making the proline-rich transmembrane protein 2 (PRRT2). The function of this protein is unknown, although it is thought to be involved in signaling in the brain. Studies show that it interacts with another protein called SNAP25, which is involved in signaling between nerve cells (neurons) in the brain. SNAP25 helps control the release of neurotransmitters, which are chemicals that relay signals from one neuron to another. Health Conditions Related to Genetic Changes Familial hemiplegic migraine At least two mutations in the PRRT2 gene have been identified in people with familial hemiplegic migraine. This condition is characterized by migraine headaches with a pattern of neurological symptoms known as aura. In familial hemiplegic migraine, the aura includes temporary numbness or weakness on one side of the body (hemiparesis). One PRRT2 gene mutation that is found in multiple people with familial hemiplegic migraine inserts an extra DNA building block (nucleotide) in the gene. (This change is written as 649dupC.) Both known mutations alter the blueprint used for making the protein and lead to production of an abnormally short PRRT2 protein that is quickly broken down. As a result, affected individuals have a shortage of PRRT2 protein. Researchers speculate that this shortage affects the function of the SNAP25 protein, leading to abnormal signaling between neurons, although the mechanism that causes familial hemiplegic migraine is unknown. It is thought that the changes in signaling in the brain lead to development of the severe headaches characteristic of the disorder. Familial paroxysmal kinesigenic dyskinesia More than 10 mutations in the PRRT2 gene have been found to cause a neurological disorder called familial paroxysmal kinesigenic dyskinesia.
    [Show full text]
  • Serum Cell-Free DNA Methylation of OPCML and HOXD9 As a Biomarker That May Aid in Differential Diagnosis Between Cholangiocarcin
    Wasenang et al. Clinical Epigenetics (2019) 11:39 https://doi.org/10.1186/s13148-019-0634-0 RESEARCH Open Access Serum cell-free DNA methylation of OPCML and HOXD9 as a biomarker that may aid in differential diagnosis between cholangiocarcinoma and other biliary diseases Wiphawan Wasenang1,2, Ponlatham Chaiyarit3, Siriporn Proungvitaya1,4 and Temduang Limpaiboon1,4* Abstract Background: Cholangiocarcinoma (CCA) is a fatal cancer of the bile duct epithelial cell lining. The misdiagnosis of CCA and other biliary diseases may occur due to the similarity of clinical manifestations and blood tests resulting in inappropriate or delayed treatment. Thus, an accurate and less-invasive method for differentiating CCA from other biliary diseases is inevitable. Methods: We quantified methylation of OPCML, HOXA9,andHOXD9 in serum cell-free DNA (cfDNA) of CCA patients and other biliary diseases using methylation-sensitive high-resolution melting (MS-HRM). Their potency as differential biomarkers between CCA and other biliary diseases was also evaluated by using receiver operating characteristic (ROC) curves. Results: The significant difference of methylation levels of OPCML and HOXD9 was observed in serum cfDNA of CCA compared to other biliary diseases. Assessment of serum cfDNA methylation of OPCML and HOXD9 as differential biomarkers of CCA and other biliary diseases showed the area under curve (AUC) of 0.850 (0.759–0.941) for OPCML which sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy were 80.00%, 90.00%, 88.88%, 81.81%, and 85.00%, respectively. The AUC of HOXD9 was 0.789 (0.686–0.892) with sensitivity, specificity, PPV, NPV, and accuracy of 67.50%, 90.00%, 87.09%, 73.46%, and 78.75%, respectively.
    [Show full text]
  • Supplementary Table 1: Adhesion Genes Data Set
    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
    [Show full text]
  • Targeting PH Domain Proteins for Cancer Therapy
    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
    [Show full text]
  • A Multi-Stage Genome-Wide Association Study of Uterine Fibroids in African Americans
    UCLA UCLA Previously Published Works Title A multi-stage genome-wide association study of uterine fibroids in African Americans. Permalink https://escholarship.org/uc/item/0mc5r0xh Journal Human genetics, 136(10) ISSN 0340-6717 Authors Hellwege, Jacklyn N Jeff, Janina M Wise, Lauren A et al. Publication Date 2017-10-01 DOI 10.1007/s00439-017-1836-1 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Hum Genet (2017) 136:1363–1373 DOI 10.1007/s00439-017-1836-1 ORIGINAL INVESTIGATION A multi‑stage genome‑wide association study of uterine fbroids in African Americans Jacklyn N. Hellwege1,2,3 · Janina M. Jef4 · Lauren A. Wise5,6 · C. Scott Gallagher7 · Melissa Wellons8,9 · Katherine E. Hartmann3,9 · Sarah F. Jones1,3 · Eric S. Torstenson1,2 · Scott Dickinson10 · Edward A. Ruiz‑Narváez6 · Nadin Rohland7 · Alexander Allen7 · David Reich7,11,12 · Arti Tandon7 · Bogdan Pasaniuc13,14 · Nicholas Mancuso13 · Hae Kyung Im10 · David A. Hinds15 · Julie R. Palmer6 · Lynn Rosenberg6 · Joshua C. Denny16,17 · Dan M. Roden2,16,17,18 · Elizabeth A. Stewart19 · Cynthia C. Morton12,20,21,22 · Eimear E. Kenny4 · Todd L. Edwards1,2,3 · Digna R. Velez Edwards2,3,9 Received: 12 April 2017 / Accepted: 16 August 2017 / Published online: 23 August 2017 © Springer-Verlag GmbH Germany 2017 Abstract Uterine fbroids are benign tumors of the uterus imaging, genotyped and imputed to 1000 Genomes. Stage 2 afecting up to 77% of women by menopause. They are the used self-reported fbroid and GWAS data from 23andMe, leading indication for hysterectomy, and account for $34 bil- Inc.
    [Show full text]
  • Targeted Genomic Sequencing Identifies PRRT2 Mutations As A
    New loci J Med Genet: first published as 10.1136/jmedgenet-2011-100635 on 30 November 2011. Downloaded from SHORT REPORT Targeted genomic sequencing identifies PRRT2 mutations as a cause of paroxysmal kinesigenic choreoathetosis Jingyun Li,1 Xilin Zhu,1 Xin Wang,1 Wei Sun,2 Bing Feng,3 Te Du,1 Bei Sun,1 Fenghe Niu,1 Hua Wei,2 Xiaopan Wu,1 Lei Dong,1 Liping Li,2 Xingqiu Cai,4 Yuping Wang,2 Ying Liu1 < Additional figure and tables ABSTRACT characterised by recurrent and brief attacks of are published online only. To Background Paroxysmal kinesigenic choreoathetosis involuntary movement.1 Familial and sporadic view these files please visit the (PKC) is characterised by recurrent and brief attacks of cases have been described. Familial PKC usually journal online (http://jmg.bmj. com/content/49/2.toc). involuntary movement, inherited as an autosomal shows an autosomal dominant inheritance pattern dominant trait with incomplete penetrance. A PKC locus with incomplete penetrance. 1State Key Laboratory of Medical Molecular Biology, has been previously mapped to the pericentromeric We previously performed linkage and haplotype Institute of Basic Medical region of chromosome 16 (16p11.2-q12.1), but the analysis in four Chinese families (family 2 and Sciences, Chinese Academy of causative gene remains unidentified. family 4 with incomplete penetrance) with similar Medical Sciences; School of Methods/results Deep sequencing of this 30 Mb region choreoathetosis clinical symptoms, and all mapped Basic Medicine, Peking Union enriched with array capture in five affected individuals the disease locus to a region between D16S3093 and Medical College, Beijing, China 2 3 2Department of Neurology, from four Chinese PKC families detected two D16S3057 at 16p11.2-q12.1.
    [Show full text]